Understanding Asymptomatic Tuberculosis
Tuberculosis (TB) is a persistent and complex disease that has plagued humanity for centuries. Despite being curable with antibiotics, it continues to spread rapidly in South Africa, where it claims over 50,000 lives annually. One of the reasons for this alarming rate is the existence of asymptomatic TB, where individuals carry the infection without showing symptoms. In this article, we explore what we know about asymptomatic TB and its implications for public health.
What is Asymptomatic TB?
Asymptomatic TB refers to a condition where an individual is infected with Mycobacterium tuberculosis but does not exhibit the classic symptoms such as persistent cough, night sweats, fever, fatigue, chest pain, and weight loss. This state can be misleading because, even though there are no visible symptoms, the bacteria may still be active and causing damage in the lungs. The severity and presentation of TB vary widely among individuals, making it difficult to distinguish from other infections or identify it as something unusual.
The Complications of Asymptomatic TB
One of the major challenges with asymptomatic TB is that it often goes undetected for extended periods. This delay can lead to more severe lung damage and eventually result in the development of symptomatic TB. Additionally, asymptomatic individuals may unknowingly transmit the disease to others, contributing to the ongoing spread of TB.
Thomas Scriba, a professor of immunology at the South African Tuberculosis Vaccine Initiative, highlights that asymptomatic TB presents on a spectrum. Some individuals may have mild illness, while others may experience more severe disease. Research suggests that asymptomatic TB typically causes less inflammation in the body compared to symptomatic disease, which could explain the absence of symptoms.
How Common is Asymptomatic TB?
There is significant uncertainty regarding the prevalence of asymptomatic TB. A systematic review and meta-analysis found that around 50% of people diagnosed with TB did not report any symptoms. However, Simon Mendelsohn, a clinical investigator at the South Africa Tuberculosis Vaccine Initiative, cautions that these numbers might be an underestimate due to the way surveys are conducted. Pre-screening components often exclude individuals with asymptomatic TB, leading to underreporting.
In South Africa’s first National TB prevalence survey, just over half of the participants with confirmed TB through molecular testing did not report any symptoms. This highlights the need for more comprehensive testing strategies to detect asymptomatic cases.
Changes in TB Testing Strategies
Traditionally, South Africa’s TB testing relied on symptomatic individuals reporting to clinics or being identified during screening drives. However, this approach often missed many cases, especially those with asymptomatic TB. To address this, the country introduced the targeted universal testing (TUT) strategy, which involves testing high-risk groups regardless of symptoms. These groups include household contacts of TB patients, people living with HIV, and those who had TB within the last two years.
The TUT strategy has shown promise in improving TB detection. For instance, the EndTB campaign launched by the National Department of Health aims to conduct 5 million TB tests in 12 months. While this target was not fully met, the initiative has significantly increased the number of TB tests performed.
Challenges in Diagnosing Asymptomatic TB
Diagnosing asymptomatic TB remains challenging due to the limitations of current tests. Most TB tests rely on sputum samples, which can be difficult to obtain, especially in individuals with lower bacterial loads. Blood-based biomarkers and other novel tests are being explored to improve detection. However, none of these tests can yet detect all cases of asymptomatic TB.
Researchers are also evaluating new methods such as tongue swabs, bioaerosol collection facemasks, exhaled breath condensate, and blood tests. A large study set to begin in 2026 in South Africa and Indonesia will assess the effectiveness of these novel tests in detecting asymptomatic TB.
Treatment and Future Directions
South Africa’s TB treatment guidelines recommend the same six-month treatment course for both symptomatic and asymptomatic cases. However, there is ongoing research into whether shorter treatment regimens could be effective for less severe cases. Clinical trials are needed to determine the best approaches for treating asymptomatic TB.
Preventative therapy is effective for latent TB infection but may not be sufficient for asymptomatic TB. There is concern that using preventative therapy for asymptomatic TB could lead to drug resistance. Therefore, it is crucial to differentiate between latent and active TB.
A new TB vaccine called M72 has shown promise in preventing TB disease in individuals with latent TB infection. If successful, this vaccine could provide protection against asymptomatic TB as well.
The Way Forward
As highlighted in this article, there are many unanswered questions about asymptomatic TB. We do not yet know how many people have it, how infectious it is, or the optimal way to treat it. However, it is clear that asymptomatic TB is a significant threat in South Africa, and relying solely on symptom screening is insufficient.
Investing in research and improving testing strategies are essential steps toward combating TB effectively. The TUT strategy and ambitious testing targets are positive developments, but continuous refinement and innovation are necessary. Better information about asymptomatic TB will help allocate resources more effectively and advocate for additional support when needed.
Until new, better tests are available, diagnostic efforts among high-risk groups should use both X-ray screening and sputum-based tests. Addressing the challenge of asymptomatic TB requires a multifaceted approach, combining scientific research, public health initiatives, and community engagement.
Bahran Hariz adalah seorang penulis di Media Online IKABARI.
